Stockwinners Market Radar for March 06, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:48 EST BioMarin says FDA extends review of BLA for Roctavian - BioMarin Pharmaceutical announced that it received notice this afternoon from the U.S. Food and Drug Administration that the agency has extended review of the company's Biologics License Application for ROCTAVIAN gene therapy for adults with severe hemophilia A. The FDA determined that the submission of the three-year data analysis from the ongoing Phase 3 GENEr8-1 study constituted a Major Amendment due to the substantial amount of additional data and set a new PDUFA Target Action Date of June 30, 2023. The company had previously communicated that this data submission could be qualified as a Major Amendment. The Phase 3 study, which included 134 participants, is the longest and largest to date for a gene therapy in hemophilia.

19:02 EST Itron signs water operations contract in Indonesia - Itron signed a contract with PT. Megalopolis Manunggal Industrial Development to improve data collection and operational efficiencies in MM2100 Industrial Town, Indonesia's fully integrated industrial estate. As part of the contract, PT. MMID will deploy Temetra, Itron's next-generation meter data collection and management solution, delivered via Itron channel partner PT. Multipar Tirta Anugra. The solution will allow PT. MMID to collect frequent and accurate water meter usage data through a unified platform, minimizing billing errors and driving innovation and conservation that aligns with Indonesia's roadmap to enter the Industry 4.0 era. Located in Bekasi West Java Province, about one hour from Jakarta, MM2100 Industrial Town continues to grow as an integrated and sustainable society. With Itron's Temetra solution, the community will drive further innovation and sustainability with the platform's automatic water data collection, which flags mis-keyed reads, resulting in reduced billing errors. PT. MMID will also take advantage of the platform's analytics to prioritize unusual water anomalies more effectively and initiate appropriate actions in response.

18:15 EST IAA 'disappointed' with Glass Lewis,' ISS' recommendations for Ritchie Bros. - IAA (IAA) announced that proxy advisory firms Glass, Lewis & Co. and Institutional Shareholder Services recommend that IAA stockholders vote to adopt the merger agreement and thereby approve Ritchie Bros. (RBA) proposed acquisition of IAA at the company's upcoming Special Meeting of Stockholders on March 14th. Stockholders of record as of the close of business on January 25 will be entitled to vote at the Special Meeting. The positive recommendations from Glass Lewis and ISS build on the support received from IAA's stockholders for the transaction with Ritchie Bros. "We are disappointed with Glass Lewis' and ISS' recommendations for Ritchie Bros., which disregard the significant benefits this transaction will bring to all stockholders. We continue to believe that combining Ritchie Bros.' and IAA's marketplace capabilities will create a unique value proposition with significantly increased earnings power and stockholder value creation relative to either company's standalone prospects."

17:57 EST DXC Technology terminates deal talks with financial sponsor - In response to market rumors and speculation, on Oct 4th, 2022, DXC Technology announced that it was approached by a financial sponsor regarding a potential acquisition of the company. Consistent with its fiduciary responsibility to maximize shareholder value, the company engaged in preliminary discussions and shared information with a financial sponsor. Due to the financial sponsor's challenges in raising the necessary capital, as a result of current market conditions, no formal proposal was received by the company and DXC has terminated the discussions. Throughout this process, the DXC team has been focused on driving the company to its inflection point. DXC remains well positioned to deliver the business it envisioned for its people, customers, and shareholders, a business that grows organically and expands margin, earnings per share and free cash flow. The Company does not intend to comment further on this matter.

17:54 EST Zynex to postpone Q4 results release, call - Zynex announced that the company will postpone the release of its fourth quarter and full year financial results and conference call initially scheduled for Monday, March 6, 2023 at 4:15 p.m. ET. The company will announce its fourth quarter and full year 2022 financial results and conference call schedule in a future press release to allow additional time to complete its year-end closing procedures.

17:43 EST Neovasc shareholders approve acquisition by ShockWave Medical - Neovasc (NVCN) is pleased to announce that its shareholders have approved the previously-announced acquisition of all of the outstanding common shares of the company by Shockwave Medical (SWAV) by way of a statutory plan of arrangement at the special meeting of shareholders.

17:36 EST International Seaways director Wheat sells 17,400 common shares - In a regulatory filing, International Seaways director Douglas Wheat disclosed the sale of 17,400 common shares of the company on March 2 at a price of $52.0609 per share.

17:34 EST Florida AG reports resolution with JetBlue over Spirit deal - Florida Attorney General Ashely Moody said that the state is "securing thousands of new jobs for Floridians and dramatically increasing the number of flights to and from Florida Cities" to resolve concerns raised by the proposed multibillion dollar merger between JetBlue Airways Corporation (JBLU) and Spirit Airlines (SAVE). Attorney General Ashley Moody said, "I am proud to take action to bring thousands of airline jobs to Florida communities, while also ensuring that Florida will see an unprecedented increase in affordable flights and airline capacity to support our growing economy." Following the completed merger between JetBlue and Spirit, the merged company must increase its seat capacity by at least 50% in both Fort Lauderdale and Orlando and must also increase its aggregate seat capacity at all other Florida airports in which JetBlue or Spirit currently operate by at least 50%. Additionally, Attorney General Moody secured employment commitments from JetBlue that will bring at least 1,000 new jobs to South Florida, at least 500 new jobs to the Orlando region, and at least 500 new jobs to support JetBlue's expanded operations at airports throughout Florida. JetBlue will extend its "no furlough" policy for Florida employees by five years and will provide increased compensation to former Spirit employees. The merged company will also maintain all Florida facilities currently in use by either JetBlue or Spirit, including Spirit's planned future headquarters in Dania Beach, at their current or planned employment levels or greater for at least five years following the merger. Reference Link

17:09 EST Annovis Bio to restate certain prior financial statements - During the course of its year-end close process, Annovis Bio concluded that there were material amounts inappropriately classified as research and development expenses which should have been classified as prepaid assets and other assets in its previously issued unaudited condensed consolidated financial statements as of and for each of the quarterly and year to date periods ended March 31, 2022, June 30, 2022 and September 30, 2022. On February 28, 2023, the Audit Committee of the Board of Directors and the Board of Directors, in consultation with management, concluded that it is appropriate to correct the errors in accounting in the company's financial statements for each of its interim periods ended March 31, 2022, June 30, 2022 and September 30, 2022 included in the associated Quarterly Reports on Forms 10-Q for each of the Non-Reliance Periods, filed with the SEC, by restating such unaudited financial information because the errors in the financial statements are material to the financial statements for each of the Non-Reliance Periods. The company will disclose in its Annual Report on Form 10-K for the year ended December 31, 2022 the restated financial statements for each of the Non-Reliance Periods. As a result, the unaudited financial statements for each of the Non-Reliance Periods should no longer be relied on. Similarly, any previously issued or filed reports, press releases, earnings releases, and investor presentations or other communications describing the company's financial statements and other related financial information covering the Non-Reliance Periods should no longer be relied upon. The company is currently in the process of determining the exact amounts and full effect of the errors in the financial statements for each of the Non-Reliance Periods. The company does not currently expect the errors to change the cash position of the company as of the end of each Non-Reliance Period. The company is currently working to complete the filing of its Annual Report on Form 10-K for the year ended December 31, 2022 as soon as practicable, which will include the Restatements. Management is assessing the effect of these Restatements on the company's internal control over financial reporting and its disclosure controls and procedures. The company expects to report at least one material weakness following completion of its analysis of the cause of these Restatements. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented or detected on a timely basis. The existence of one or more material weaknesses precludes a conclusion by management that the company's disclosure controls and procedures and internal control over financial reporting are effective. As a result of the material weakness or material weaknesses, the company believes that its internal control over financial reporting was not effective, and its disclosure controls and procedures were not effective for the Non-Reliance Periods.

17:09 EST Carriage Services names Kian Granmayeh as CFO - Carriage Services (CSV) announced the appointment of Kian Granmayeh as Executive Vice President, CFO and Treasurer, effective March 13. Prior to joining Carriage, Granmayeh served as Executive Vice President and CFO for Tellurian (TELL), a publicly traded company in the liquefied natural gas sector.

16:51 EST Rio Tinto consents to $15M civil penalty to settle SEC 'bribery scheme' charges - The Securities and Exchange Commission announced charges against global mining and metals company, Rio Tinto plc, for violations of the Foreign Corrupt Practices Act, FCPA, arising out of a bribery scheme involving a consultant in Guinea. The company has agreed to pay a $15M civil penalty to settle the SEC's charges. The SEC's order finds that, in July 2011, Rio Tinto hired a French investment banker and close friend of a former senior Guinean government official as a consultant to help the company retain its mining rights in the Simandou mountain region in Guinea. The consultant began working on behalf of Rio Tinto without a written agreement defining the scope of his services or deliverables. Eventually the mining rights were retained, and the consultant was paid $10.5 million for his services, which Rio Tinto never verified. The SEC's investigation uncovered that the consultant, acting as Rio Tinto's agent, offered and attempted to make an improper payment of at least $822,000 to a Guinean government official in connection with the consultant's efforts to help Rio Tinto retain its mining rights. Furthermore, none of the payments to the consultant was accurately reflected in Rio Tinto's books and records, and the company failed to have sufficient internal accounting controls in place to detect or prevent the misconduct. The mine has not been developed by Rio Tinto...Rio Tinto consented to the SEC's order without admitting or denying the findings that it violated the books and records and internal accounting controls provisions of the Securities Exchange Act of 1934 and agreed to pay a $15M civil penalty. Reference Link

16:41 EST Barnes & Noble Education reschedules Q3 earnings release, call - Barnes & Noble Education announced that the company is rescheduling its third quarter Fiscal Year 2023 earnings report previously scheduled for Tuesday, March 7, 2023 at 8:30 a.m. Eastern Time. The rescheduling allows the company adequate time to close on its amended and extended asset-backed revolving and term loan credit facilities, which the company expects to close on or before Thursday, March 9, 2023. The company intends to report Fiscal 2023 third quarter earnings results on Thursday, March 9, 2023, after market close. The company will host an investor conference call at 4:30 p.m. Eastern Time on Thursday, March 9, 2023, to review the company's financial results and operations.

16:34 EST CareDx says won't participate in Raymond James conference on scheduling conflict - CareDx announced that the company has determined not to participate in the Raymond James & Associates' 44th Annual Institutional Investors Conference scheduled for later today "in light of scheduling conflicts." The company "looks forward to providing its next corporate update in the near term," CareDx stated in a press release.

16:31 EST Fat Brands CEO Andy Wiederhorn to step aside - FAT Brands announces that its founder and CEO, Andy Wiederhorn, will transition to a new role as an outside consultant and strategic advisor to the company effective May 5. Wiederhorn will remain a FAT Brands Board member and his family office, Fog Cutter Holdings LLC, will continue as the controlling shareholder of FAT Brands. The appointment of an interim CEO will be announced prior to the transition date, and Wiederhorn will continue as CEO until then. In his strategic advisory role, Wiederhorn will continue to support the management team and the company while focusing his time on the company's long-term strategy and capital allocation plans. In transitioning from his role as CEO, Wiederhorn seeks to eliminate the distraction of the previously announced government investigation tied to him, and allow senior management to focus on continuing to drive shareholder value.

16:24 EST Kaleyra announces 1-for-3.5 reverse stock split - Kaleyra announced that the company's Board of Directors has approved a 1-for-3.5 reverse stock split of the company's issued and outstanding common stock. Beginning with the opening of trading on or about March 9, Kaleyra's common stock will trade on the New York Stock Exchange on a split-adjusted basis under the new CUSIP number 483379202 and will continue to trade under the symbol "KLR."

16:15 EST WW to acquire Sequence for $132M in cash, stock - WW has entered into a definitive agreement to acquire Weekend Health, Inc., d/b/a Sequence, a subscription telehealth platform offering access to healthcare providers specializing in chronic weight management. Sequence integrates the patient and clinician experience for ongoing, clinical care and medication management while providing support in navigating the insurance approval process. Pursuant to the terms of the merger agreement, WW will acquire Sequence in a cash and equity transaction valued at $132M, inclusive of a minimum of $26M of Sequence's cash. The effective net purchase price is $106M. The $132M will be paid as follows: $100 million at the closing of the transaction, of which $65 million will be paid in cash and $35M in the form of 8.065 million newly issued shares of common stock of WW; $16M in cash on the first anniversary of the closing and $16M in cash on the second anniversary of the closing. The transaction, which is subject to customary closing conditions, is expected to close during the second quarter of 2023.

16:08 EST Cara sees cash, cash equivalents sufficient to fund ops into at least 1H24 - Cara expects that our current unrestricted cash and cash equivalents and available-for-sale marketable securities, including collaborative revenue from our share of the profit from KORSUVA injection, will be sufficient to fund our currently anticipated operating plan into at least the first half of 2024.

16:00 EST Mr. Cooper names Kurt Johnson CFO, Christine Paxton CRCO - Mr. Cooper Group announced two executive leadership appointments today - the appointment of Kurt Johnson to Chief Financial Officer and Christine Paxton as Executive Vice President and Chief Risk and Compliance Officer. Johnson joined the company in 2015 and most recently served as Chief Risk and Compliance Officer, responsible for credit and market risk management and leading the risk and compliance organization. With 25 years in the mortgage industry, Johnson has experience in originations, servicing, treasury, portfolio management and financial planning. In his time with Mr. Cooper, Johnson also led the multi-year Project Titan servicing transformation initiative and oversaw critical technology and process enhancements for our platform. In 2019, Johnson became the company's Chief Credit Officer responsible for setting all Credit Risk related policy and governance before being promoted to his role as Chief Risk and Compliance Officer in early 2021. "With his decades of experience in mortgage-banking, strong relationships with government and industry stakeholders and a detailed understanding of our platform, Kurt is already a major force at the company and in the industry. In his new role, he will be instrumental in setting the company on the path to delivering strong and rising investor returns," said Jay Bray, Chairman and CEO of Mr. Cooper Group. As Johnson assumes his new role, Jaime Gow will transition from Chief Financial Officer to a strategic advisor role through October.

15:19 EST Genelux Corp trading halted, volatility trading pause

15:02 EST Raytheon Technologies' Pratt & Whitney awarded $5.2B contract - Pratt & Whitney, a Raytheon Technologies business, announced that it has been awarded a $5.2B contract to support production of the 15th and 16th lots of F135 engines, with an option to award a 17th Lot, powering all three variants of the F-35 Lightning II fighter aircraft. The Lots 15-17 production contract funds production of 278 F135 engines with an option to order up to a total of 518 engines. The contract also includes program management, engineering support, production support and tooling. The total contract value for lots 15-17, with exercised options, is approximately $8B and will fund over 418 F135 engines with options for the U.S. as well as international customers.

14:01 EST Microsoft introduces Dynamics 365 Copilot - Noting that according to its recent survey on business trends, nearly 9 out of 10 workers hope to use AI to reduce repetitive tasks in their jobs, Microsoft introduced its Dynamics 365 Copilot, saying that organizations will be able to "empower their workers with AI tools built for sales, service, marketing, operations and supply chain roles. These AI capabilities allow everyone to spend more time on the best parts of their jobs and less time on mundane tasks." "Customer relationship management, or CRM, and enterprise resource planning, or ERP, systems have long been mission-critical customer and business data sources; however, they frequently require burdensome tasks like manual data entry, content generation and notetaking. Dynamics 365 Copilot takes advantage of recent advancements in generative AI to automate these tedious tasks and unlock the full creativity of the workforce. Dynamics 365 Copilot puts CRM and ERP to work for business users to accelerate their pace of innovation and improve business outcomes in every line of business," the company explains. Microsoft highlights, among other things, that "Dynamics 365 Copilot drafts contextual answers to queries in both chat and email, in addition to providing an interactive chat experience over knowledge bases and case history so this AI-powered expertise is always available to answer questions... With Copilot in Dynamics 365 Customer Insights, marketers can curate highly personalized and targeted customer segments by having a dialogue with their customer data platform using natural language... Marketers can also use Dynamics 365 Copilot to effortlessly get inspiration for fresh email campaign content based on a simple request. Copilot makes suggestions based on key topics entered by the marketer, the organization's existing marketing emails, as well as from a range of internet sources to increase the relevance of generated ideas... Lastly, Copilot in Microsoft Supply Chain Center, which Microsoft Dynamics 365 Supply Chain Management customers can access, will proactively flag external issues such as weather, financials and geography that may impact key supply chain processes." Reference Link

13:32 EST JetBlue says updated data supports 'pro-competitive impact' of Spirit merger - JetBlue (JBLU) released updated data that the company claims "further supports the disruptive role of the airline on the dominant, higher-price legacy carriers, and the pro-competitive impact the merger with Spirit will have on the industry." In a press release, JetBlue added: "The Big Four airlines have a lock on about 80% of the market. JetBlue's combination with Spirit allows it to create a compelling national challenger to these dominant airlines, while also ensuring ULCC options remain available in overlap markets. While JetBlue, with its highly unique combination of low fares and great service, will be able to expand with new national breadth as a result of the transaction, it will remain a significantly smaller player than each of the Big Four airlines. According to the data, a combined JetBlue and Spirit will have only about 9% market share, compared to about 16-24% for each of the four largest airlines, but the added scale and ability to further grow will result in meaningful competition on more routes to more destinations and greater opportunities for Crewmembers and Team Members of both airlines."

13:13 EST Murchinson issues presentation detailing need for change at Nano Dimension - Murchinson Ltd, the largest shareholder with approximately 5.2% of the outstanding shares of Nano Dimension Ltd., issued a presentation outlining why it believes change is urgently needed at Nano Dimension. Shareholders have the opportunity to vote at the upcoming Special General Meeting of Shareholders, "in spite of the Company's efforts to declare the meeting illegal and stop the voices of shareholders from being heard." Key takeaways from the presentation include: "The Company has drastically underperformed during Yoav Stern's Chairmanship. Nano Dimension shares have declined by more than 77% since Mr. Stern was appointed Chairman in 20211. Further, the Company currently has a negative enterprise value of more than $400 million - reflecting investors' concern regarding the current Board and management team's continued destruction of value. The bottom line is that the longer the Stern-led Board remains in place, the greater the risk of further value erosion. The Stern-led Board has overseen terrible corporate governance and failed to hold management accountable. Stern's Chairmanship has been characterized by a series of damaging capital allocation missteps. Murchinson is seeking to establish accountability and transparency and ensure the Board prioritizes protecting value for ALL shareholders. Murchinson believes a refreshed board can meaningfully enhance value."

12:59 EST Ambrx Biopharma trading resumes

12:54 EST Ambrx Biopharma trading halted, volatility trading pause

12:34 EST Spirit Airlines falls after Bloomberg report of DOJ merger lawsuit

12:16 EST Comerica Bank names Jeff Banks SVP, chief data and analytics officer - Comerica Incorporated announced that Jeff Banks has been named to the new role of Senior Vice President, Chief Data and Analytics Officer. He will report to Megan Crespi, Senior Executive Vice President, COO. "Effectively harnessing the power of data and analytics is critical to our ability to meet and exceed the evolving needs of our customers," said Crespi. "Jeff's leadership and experience in data management will enable Comerica to establish a strong data-driven foundation on which to expand our capabilities."

12:04 EST Merck says MK-0616 'significantly reduced' LDL-C in Phase 2b study - Merck announced results from the Phase 2b clinical trial evaluating MK-0616, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 inhibitor in adults with hypercholesterolemia. The primary objective of the study was to evaluate the percent change in low density lipoprotein cholesterol from baseline to week eight for four doses of MK-0616 versus placebo. At week eight, all doses of MK-0616 "significantly reduced" LDL-C compared to placebo and the placebo-adjusted reduction from baseline ranged from 41.2% to 60.9%, Merck said in a statement. MK-0616 was generally well-tolerated at all four doses studied, the company added. "Despite widely available statin treatments, millions of patients are still not able to lower their cholesterol to the guideline-recommended levels and as a result are at increased risk for serious cardiovascular complications associated with atherosclerosis," said Dr. Christie Ballantyne, principal investigator of the study and Professor of Medicine at Baylor College of Medicine. "Currently available PCSK9 inhibitors are effective tools to treat hypercholesterolemia but must be administered by injection. With these promising data showing that MK-0616 reduced LDL-C levels by up to 60.9%, MK-0616 should be further studied for its potential as a daily oral medicine." "These data reinforce our confidence that MK-0616 could become the first oral PCSK9 inhibitor, with the potential to change the way patients with hypercholesterolemia who need additional LDL-C reduction are treated. This may allow many more patients to reach their LDL-C treatment goals," said Dr. Joerg Koglin, vice president, global clinical development, Merck Research Laboratories. "We look forward to advancing this program into Phase 3 development in the second half of this year."

12:00 EST United States Natural Gas Fund falls -13.4% - United States Natural Gas Fund is down -13.4%, or -$1.32 to $8.56.

12:00 EST Vistra rises 14.5% - Vistra is up 14.5%, or $3.11 to $24.52.

12:00 EST Azul rises 45.7% - Azul is up 45.7%, or $1.90 to $6.06.

11:12 EST Ritchie Bros. board 'strongly disagrees' with Glass Lewis, ISS recommendations - Ritchie Bros. Auctioneers (RBA) provided the following statement in response to reports issued by Glass Lewis & Co. and Institutional Shareholder Services in connection with the Company's pending acquisition of IAA (IAA): "The Ritchie Bros. Board of Directors and management team strongly disagree with the recommendations issued by Glass Lewis and ISS. We continue to urge Ritchie Bros.' shareholders to follow the Board's recommendation and vote 'FOR' all proposals listed on the WHITE proxy card TODAY. The IAA transaction is expected to unlock substantial additional value that neither Ritchie Bros. nor IAA could achieve on its own, and we are confident in our ability to realize it. Integration planning is well underway. We are ready to hit the ground running as soon as the transaction closes. Our experience in M&A and the automotive sector as well as our proven record of execution give us confidence that we can seamlessly bring the companies together. The Ritchie Bros. Board and management team are committed to acting in the best interests of all Ritchie Bros.' shareholders and to building long-term value and driving superior shareholder returns. We are confident that the IAA transaction represents the most compelling opportunity to position Ritchie Bros. for long-term success. The Ritchie Bros. management team has consistently delivered on its promises and driven substantial value for shareholders. We believe there is every reason for shareholders to support the Ritchie Bros. Board and management and to have confidence that we will continue to execute through the IAA acquisition. A vote 'FOR' the IAA acquisition is a vote 'FOR' the team and 'FOR the strategy that are delivering outstanding results for shareholders."

10:32 EST Masimo announces findings of prospective study of Masimo PVi - Masimo announced the findings of a prospective study published in the British Journal of Neurosurgery in which Dr. Ankita Dey and colleagues at institutions in Bathinda and Pondicherry, India evaluated the use of noninvasive, continuous Masimo PVi, as part of goal-directed fluid therapy, to guide intraoperative fluid administration during neurosurgery - the first study to evaluate PVi in this surgical scenario - by comparing it to a parameter obtained invasively, stroke volume variation. The researchers concluded that "PVi and SVV are equally effective for guiding intraoperative goal-directed fluid therapy in adult neurosurgical patients scheduled for elective craniotomy for supratentorial brain tumors. However, PVi, being a noninvasive parameter, may be preferable." Noting the value of GDFT for neurosurgical patients in particular, but that most of the dynamic parameters traditionally used to guide GDFT, such as SVV, are invasive, requiring the use of an intra-arterial catheter which is associated with a variety of complications, the researchers sought to determine whether a noninvasive parameter, PVi, whose measurements are derived from the photoplethysmographic waveform, might serve as a reliable predictor of fluid responsiveness in such a population. PVi, or pleth variability index, is a measure of the variations in perfusion index over the respiratory cycle, and is indicated as a noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients. To test their hypothesis, the researchers randomly divided 60 adult patients undergoing elective craniotomy into two groups: one whose intraoperative fluid administration was guided by PVi nd the other, by SVV. In the PVi group, patients were monitored using Masimo Radical-7 Pulse CO-Oximeters with noninvasive pulse oximetry fingertip sensors. In the SVV group, SVV was invasively measured using an Edwards Lifesciences Vigileo/FloTrac device connected to a cannulated radial artery. The researchers compared the total amount of intravenous fluid administered during surgery, as well as serum lactate and serum creatinine levels at pre-determined time points, the brain relaxation score at dural opening and closure, and correlation between PVi and SVV values. They also compared duration of mechanical ventilation and length of hospital stay. As noted in the table below, the researchers found that the volume of fluid administered intraoperatively was significantly higher in the SVV group. The other parameters and outcomes they measured were comparable between the two groups: serum lactate, serum creatinine, brain relaxation score, duration of mechanical ventilation, and length of hospital stay, as noted below. The researchers also observed "a moderate to strong correlation between SVV and PVi at corresponding points of time during the intraoperative period. This suggests that PVi, derived noninvasively from the pulse oximetry waveform, is a reliable indicator of fluid responsiveness." The researchers concluded, "Based on the findings of our study, we conclude that PVi and SVV are equally effective for guiding intraoperative goal directed fluid therapy in adult neurosurgical patients scheduled for elective craniotomy for supratentorial brain tumors. However, PVi, being a noninvasive parameter, may be preferable." They continued, "The two groups in our study were comparable with respect to serum creatinine and serum lactate measured at predetermined time points intraoperatively and post operatively. The two groups were also comparable with respect to brain relaxation scores at dural opening and dural closure. There was moderate to strong correlation between SVV and PVi at corresponding time points intraoperatively. The duration of mechanical ventilation and the length of hospital stay was also comparable between the two groups."

10:02 EST L3Harris Technologies receive contract from Lockheed Martin for Viper Shield - L3Harris Technologies (LHX) announced receiving an undefinitized contract from Lockheed Martin (LMT) to procure long-lead material for the Viper Shield electronic warfare system to accelerate global product delivery. The AN/ALQ-254(V)1 Viper Shield supports the Lockheed Martin F-16 Block 70/72 aircraft production for the global F-16 fleet and was designed as the baseline EW system for the aircraft. This contract, in conjunction with a future full-rate contract award for Viper Shield ship sets, will enable planned production EW capability deliveries for customers worldwide. The Viper Shield program remains on schedule and slated for installation on the next-generation F-16 aircraft for multiple international air defense forces. Viper Shield will return to the Lockheed Martin Systems Integration Lab later this year with newly integrated hardware and software to test the next planned increment of capabilities with the F-16 Block 70/72 aircraft.

10:00 EST Unisys falls -11.1% - Unisys is down -11.1%, or -54c to $4.34.

10:00 EST Kennedy Wilson rises 9.1% - Kennedy Wilson is up 9.1%, or $1.52 to $18.24.

10:00 EST Azul rises 45.0% - Azul is up 45.0%, or $1.87 to $6.03.

09:47 EST IAA falls -7.6% - IAA is down -7.6%, or -$3.12 to $38.06.

09:47 EST United States Natural Gas Fund falls -11.9% - United States Natural Gas Fund is down -11.9%, or -$1.18 to $8.71.

09:47 EST Kennedy Wilson rises 11.2% - Kennedy Wilson is up 11.2%, or $1.88 to $18.60.

09:40 EST Digital Media Solutions Inc trading resumes

09:35 EST RRDS selects Mullen Automotive as exclusive provider of Class 1 EV cargo vans - Mullen Automotive announces teaming up with Rapid Response Defense Systems to fast-track U.S. Federal Government opportunities for potential large-scale vehicle fleet orders. RRDS, one of the country's leading small business federal contractors, has executed over 2,500 federal government delivery orders since 2014. The company currently holds a prime seat on 12 Indefinite Delivery/Indefinite Quantity federal contracts with combined funding ceilings of $4B.

09:33 EST Harbor Custom Development reduces company head count by 56% - Harbor Custom Development announced the Company has downsized its land development infrastructure division, reducing the Company's total head count by 56% since Q3 while selling off $7.5M in heavy equipment that was previously utilized by the land development infrastructure division. Lance Brown, CFO added, "The sale of the equipment has reduced our annual cash outlay on loans and lease payments associated with this equipment by more than $2M annually. The Company also eliminated approximately $1.1M in annual depreciation expense associated with the sale. Downsizing the land development infrastructure division and wrapping up our fee build projects and quarry operations is a good outcome for us as these projects had a negative impact on our 2022 cash flows and financial results."

09:28 EST Bayou Bend expands carbon capture project to onshore Southeast Texas - Bayou Bend, a carbon capture and sequestration project located along the Texas Gulf Coast, announced an expansion of its carbon dioxide storage footprint through the acquisition of nearly 100,000 acres onshore in Chambers and Jefferson Counties, Texas. The increased acreage positions Bayou Bend to be one of the largest carbon storage projects in the United States. Bayou Bend is a joint venture between Chevron (CVX), through its Chevron New Energies division, Talos Energy (TALO), through its Talos Low Carbon Solutions division, and Carbonvert.

09:25 EST Digital Media Solutions ends strategic review process, reduces 14% of workforce - Digital Media Solutions announced that its board of directors completed its previously announced review to evaluate potential strategic alternatives. The board has unanimously determined that continuing to execute on the company's strategic plan as an independent, public company is in the best interest of the company and its stockholders at this time. Over the course of the review, the board, in consultation with its financial and legal advisors, engaged in a proactive process to evaluate strategic opportunities. As part of the review, the company contacted and held discussions with numerous third parties, which included strategic and financial parties, regarding, among other alternatives, a potential sale of the company. The company received initial proposals from multiple third parties during this process. In addition to these indications of interest from third parties, as previously announced, on September 8, 2022, the company received a proposal from Prism Data, an investment vehicle affiliated with CEO Joseph Marinucci and COO Fernando Borghese, for an acquisition of the company at a per-share price of $2.50. Consistent with its fiduciary duties, the board in its strategic review has considered numerous strategic alternatives, including a sale of the company, acquisitions, divestitures, financings and other transactions towards enhancing shareholder value. On March 3, Prism notified the company that it was withdrawing the proposal. The board has determined not to further pursue a potential sale of the company at this time. The board remains committed to maximizing shareholder value, and intends to continue to consider other strategic alternatives, including acquisitions, divestitures, financings and other transactions towards enhancing shareholder value. The company also announced that it has implemented a restructuring plan designed to create efficiency, save costs and strategically target areas with growth potential. With the business consolidation into DMS core service offerings, the Restructuring resulted in a 14% reduction of the DMS workforce, the financial benefits of which will accrue in future periods.

09:19 EST Crown Electrokinetics agrees to build fiber optic networks in Northwest U.S. - Crown Electrokinetics announced that it has entered into an agreement with a subsidiary of one of the largest telecommunication infrastructure companies in the United States. The agreement expands Crown's customer base and geographic coverage with operations now in Washington, and soon to expand to Oregon and California. Doug Croxall, Crown Electrokinetics CEO and Chairman stated, "Our fiber optics division is focused on growing its customer base and with this agreement we have added our second customer. Expanding our customer base importantly increases our revenue opportunities, alleviates customer concentration risk, and makes growth more predictable. We are actively involved in multiple conversations with other prospective customers within the United States and look forward to sharing more customer wins in the near future."

09:18 EST Better Choice Company, Pet Supermarket announce partnership - Better Choice Company announced a partnership with Pet Supermarket to offer the Better Choice Halo Brand, a super-premium pet food. Beginning on March 2, 2023, Pet Supermarket will carry a range of Halo's natural pet food products, including their popular Halo Elevate line of foods. Pet Supermarket is a trusted destination for pet foods and supplies across the Southeastern United States. Halo Elevate will be available in over 75 stores. "At Halo, we are committed to providing pets with the best possible nutrition, and we are excited to partner with Pet Supermarket to make our products more widely available," said Lionel Conacher, CEO of Halo. "We believe that by working together, we can make a meaningful impact on the lives of pets and their owners."

09:17 EST Philips announces presentations on clinical studies at ACC.23/WCC - Royal Philips announced the presentation of various clinical study results at this year's Annual Scientific Session & Expo of the American College of Cardiology/World Congress of Cardiology, ACC.23/WCC, event that confirm Philips' commitment to clinically validating its innovations in cardiac and cardiovascular care. Reduced risk of one-year mortality when intravascular imaging used during PCI procedures: Dr. Eric Secemsky at Beth Israel Deaconess Medical Center and his collaborators conducted a high-quality real-world evidence study of Medicare data for over one million patients undergoing PCI procedures between January 1, 2013, and December 31, 2019. The preliminary results reveal that the use of intravascular imaging technologies as an adjunct to angiography rose by 62% during the period and is associated with superior patient outcomes. The potential for further strong growth is supported by a recent review published in the Journal of the American College of Cardiology, which "advocates broader use of these technologies as a part of contemporary practice" and recommends that "IVI capability should be included in all U.S. CCLs." Timely removal of infected CIEDs: The CIED Infection Medicare Study of clinical practice was conducted by Dr. Sean Pokorney and his team at the Duke Clinical Research Institute, which analyzed the records of more than one million CIED implant patients in the 'U.S. 100% Medicare fee-for-service' population covering the period January 1, 2006, to December 31, 2019. The study represented a nationwide analysis of CIED infection care, and as already reported by Dr. Pokorney at last year's ACC, demonstrated that approximately 4 in 5 patients were not treated according to ACC/AHA/HRS/EHRA Class I consensus recommendations and guidelines for CIED infection, which recommend full system extraction ideally within 3 days. Of the 9,867 patients diagnosed with a CIED infection 12 months or more after implantation, only 13.3% underwent extraction within six days and only 5.2% between seven and 30 days. Performance and safety of 3D intracardiac echocardiography: The prospective, non-randomized, multi-center, observational study into the safety and performance of Philips 3D Intracardiac Echocardiography Catheter - VeriSight Pro - was led by Dr. Mohamad Alkhouli at Mayo Clinic School of Medicine. The study was based on a cohort of 155 patients evaluated for a range of percutaneous cardiac intervention procedures, including left atrial appendage occlusion, cardiac ablation, heart valve replacement, and patent foramen ovale as well as atrial septal defect 'hole-in-the-heart' repair procedures. During the study, patients were followed until discharge or 48 hours after their procedure, with safety demonstrated by the fact that no periprocedural device-related adverse events were reported. Philips VeriSight Pro 3D ICE demonstrated acceptable or better image quality compared to TEE or competitive ICE technology in over 95% of the procedures. VeriSight Pro 3D ICE was considered to be an acceptable or better surrogate to TEE 89.7% of the time.

09:16 EST Camping World to exit and restructure operations of Active Sports subsidiary - In a regulatory filing, Camping World disclosed that on March 1, management of the company determined to implement plans to exit and restructure operations of its indirect subsidiary, Active Sports, LLC, a specialty products retail business, as part of its review of underperforming assets and business lines and concluded that a material charge for impairment would be incurred in connection therewith. "These plans, when completed, will result in the liquidation of primarily all of its assets and closure of the Active Sports business and are anticipated to result in the impairment of certain long-lived assets associated with the Active Sports business. The company currently estimates the total impairment charges associated with these restructuring activities to be between $11 million and $16 million which includes property and equipment, operating lease assets, and intangibles. The company expects that none of the foregoing impairment charges will directly result in future cash expenditures," the filing stated.

09:14 EST Digital Media Solutions Inc trading halted, news pending

09:14 EST Immersion files patent infringement suits against Xiaomi in Europe and India - Immersion (IMMR) announced that it has filed patent infringement lawsuits against several companies of the Xiaomi-Group (XIACF) in Germany, France and India. Immersion filed complaints against Xiaomi-Group companies and their agents in the Dusseldorf Regional Court in Germany, the Tribunal judiciaire de Paris in France, and the High Court of Delhi, at New Delhi, in India. The complaints allege that Xiaomi's smartphones, including the Xiaomi 12, infringe Immersion's patents that cover various uses of haptic effects in connection with such smartphones. Immersion is seeking injunctions that would allow Immersion to prohibit Xiaomi from selling the infringing smartphones in Germany, France and India, as well as costs and damages as compensation for such infringement. "Immersion and its employees are proud of its rich history of almost 30 years of inventing innovative haptic technologies that allow people to use their sense of touch to engage with products and experience the digital world around them. Our intellectual property is relevant to many of the most important ways in which haptic technology is and can be deployed, and, in the case of smartphones, haptics is crucial to an immersive user experience. Many of our licensed customers are market leaders that benefit from our technology," said Eric Singer, CEO of Immersion.

09:13 EST Rent The Runway adds extra item to every subscription shipment - Rent the Runway announced that it is evolving its customer experience by permanently adding an extra item to every shipment of its iconic rental subscription program, the first move in what the company is calling its "Era of Extra" focused on continued investment in the customer. "We believe that there is strategic value in giving her more items in her subscription, because we have seen from years of testing that providing an additional item drives higher loyalty and engagement," said Jennifer Hyman, Co-Founder and CEO of Rent the Runway. "Especially at a time when consumers are doing the math on what they spend and many companies are taking away rather than giving back, we are confident that this is the right move for our customer and for our business. The more items she receives from RTR, the more she wears. When she rents more frequently, we believe that she is more likely to widen her use cases, share RTR more with her friends and be a subscriber longer."

09:12 EST WidePoint signs mobile, telecom managed services contract - WidePoint Corporation has executed a new contract to provide Mobile and Telecom Managed Services to a Standard & Poor's 500 and FTSE4Good Food & Beverage company.

09:09 EST Seanergy Marine regains compliance with Nasdaq minimum bid price rule - Seanergy Maritime Holdings announced that it has received written notification from the Nasdaq Listing Qualifications department of The Nasdaq Stock Market, confirming that the Company has regained compliance with the Nasdaq Listing Rule 5550(a)(2) concerning the minimum bid price of the Company's common stock and the matter is now closed.

09:09 EST Credo Technology and EFFECT Photonics team on power coherent DSP solutions - Credo and EFFECT Photonics announced plans to collaborate on the development of coherent Digital Signal Processor ,DSP, merchant ICs, featuring industry-leading power dissipation and performance. The DSPs are expected to deliver the capacity and reach needed to meet the explosive demands for connectivity and bandwidth and enable cost-effective network upgrades over existing physical fiber infrastructure. These merchant silicon offerings have the added benefit of giving customers the flexibility to choose from a variety of transceiver suppliers. Credo and EFFECT Photonics Announce Collaboration on High-Performance, Ultralow Power Coherent DSP Solutions The two companies will work together to develop new coherent DSP products featuring EFFECT Photonics' coherent DSP technology and Forward Error Correction, FEC , combined with Credo's high-speed SerDes, I/Os, Analog to Digital Converters, ADCs , and Digital to Analog Converters DACs . Credo will manufacture and manage the sales and supply channels of the co-developed merchant ICs, and provide complete design services and customer support.

09:07 EST CareCloud, KabaFusion partner to transform patient care - CareCloud announced a partnership with KabaFusion aimed at further optimizing the financial performance of the home-infusion provider through revenue cycle management. This partnership will leverage CareCloud's RCM experience to streamline processes, reduce denials, and increase revenue captured for KabaFusion. Hadi Chaudhry, president and chief executive officer of CareCloud, echoed these sentiments, stating that the partnership presents tremendous opportunities for both CareCloud and KabaFusion. "With our knowledge and experience in revenue cycle management and the home healthcare industry, we are excited to work closely with KabaFusion and further develop this exciting collaboration."

09:05 EST Macom acquires Linearizer Communications for $49M - Macom announced that it has acquired Linearizer Communications, a developer of products located in Hamilton, New Jersey. Linearizer was founded in 1991 by Allen Katz and specializes in non-linear microwave predistortion for use in terrestrial, avionic and space-based applications and high-performance microwave photonic solutions for use in the industrial and defense markets. The Linearizer team uses proprietary design and manufacturing techniques to produce its high-performance components and subsystems. Linearizer has a long history of service to its customer base, which is primarily in North America. The purchase price was approximately $49M, funded with cash-on-hand. Macom plans to maintain and expand Linearizer's current manufacturing and engineering facility. The acquisition is expected to be immediately accretive to Macom's adjusted earnings per share. However, due to the timing of the acquisition closing, it is not expected to have a material impact on MACOM's fiscal second quarter of 2023 revenue and adjusted EPS.

09:05 EST Cardinal Health, Signify Health collaborate on in-home health management - Cardinal Health (CAH) announced its collaboration with Signify Health (SGFY) to offer in-home clinical and medication management services through its Outcomes business. This collaboration will help reduce costs and eliminate gaps in care for more than 2.3M members nationwide to support their treatment journey from prescription to pharmacy to home. The collaboration will initially focus on addressing interventions recommended for Medicare Advantage members of joint clients and may expand into additional services, such as population health programs, and additional clinical interventions.

09:04 EST Carnegie Private Wealth launches with support from LPL Financial - LPL Financial announced that three teams of financial advisors have joined forces for the launch of a new independent practice, Carnegie Private Wealth, through affiliation with LPL Strategic Wealth Services, a modern breakaway solution for advisors seeking to gain more control over their business. The advisors reported having served a collective $1.45 billion in advisory, brokerage and retirement plan assets. They join LPL from Wells Fargo Advisors.

09:03 EST Cabot to establish new technology center in Munster - Cabot announced its plans to establish a new technology center in Munster, Germany. The new technology center will focus on technical collaboration with customers in order to accelerate application innovation for Cabot's battery materials product lines within Europe. The new facility furthers Cabot's investment plans to expand its global battery materials footprint and will play a critical role in Cabot's continued delivery of world-class, innovative materials to customers in the Europe, Middle East, and Africa, or EMEA, region and across the globe. The new EMEA Technology Center will enable Cabot to enhance its battery materials development capabilities and continue to strengthen its technology engagements with other participants in the battery industry through enhanced collaboration and innovation with battery manufacturers, electric vehicle customers and partners in Europe. In addition, the center will feature advanced testing equipment to provide technical application capabilities to serve the battery industry globally. The EMEA Technology Center is expected to commence operations by April 2023, with a planned expansion to be completed in 2024.

09:01 EST Heron Therapeutics announces U.S. commercial launch of APONVIE - Heron Therapeutics announced APONVIE (aprepitant) injectable emulsion, is now commercially available for intravenous use in adults for the prevention of PONV. Delivered via a single IV injection, APONVIE reaches drug levels associated with greater than or equal to97% receptor occupancy in the brain within five minutes and maintains therapeutic plasma concentrations for at least 48 hours. This ready-to-use, easy to administer, innovative IV formulation ensures rapid and consistent exposure in patients undergoing surgery. Treatment with aprepitant resulted in approximately 50% fewer patients vomiting in the first 24 and 48 hours compared to the current standard-of-care, IV ondansetron.

08:55 EST Exela Technologies expects $65M to $75M in savings for FY23 - Exela Technologies announced updates to its 2023 operational performance improvement objectives. During the fourth quarter, the company announced operational performance improvement targets by focusing on automation led efficiencies. The company has identified additional savings to help restore historically higher margins relative to recent financial reporting periods and plans to right-size the organization in the face of continuing tight job markets and higher employee costs. Exela expects savings in the range of $65M to $75M for 2023, including the initiatives announced in Q4 2022. The company's actions include headcount optimization, real estate reduction and increased cloud usage. The company's global workforce is expected to shrink; however, the company will continue to maintain substantial flex capacity through its cloud-based WFA platforms to quickly ramp growth as needed. The company looks forward to providing investors with additional updates during earnings calls.

08:51 EST BlackLine announces leadership succession - BlackLine announced that its Board of Directors has appointed founder, director and former Chief Executive Officer, Therese Tucker, and Board Chair, Owen Ryan, as Co-CEOs, effective immediately. In connection with these changes, Thomas Unterman, who has served as a director since 2010, has been named Lead Independent Director, and Ryan will remain Chair. Tucker and Ryan succeed Marc Huffman, who has agreed to serve as an advisor to the Company for the next year.

08:49 EST AIM ImmunoTech issues letter to stockholders - AIM ImmunoTech issued a letter to stockholders highlighting key accomplishments in 2022 and outlining corporate objectives for 2023. "Over the course of the past year, the AIM management team and Board have worked dedicatedly to position the Company for continued success... We have continued to be encouraged by the data we have seen to date demonstrating Ampligen's potential for the treatment of multiple types of cancers, immune disorders, and viral diseases, including COVID-19, and continue to establish a growing body of data as a priority. With 10 active clinical programs, 2023 is poised to be a busy and exciting year. In addition to a number of publications for pipeline data expected throughout the year, anticipated upcoming milestones include: Q1 2023: Post-COVID Conditions: Commence Phase 2 study; Locally Advanced Pancreatic Cancer: Enroll first patient in Phase 2 study. Q2 2023: Locally Advanced Pancreatic Cancer: Dose first patient in Phase 2 study; Post-COVID Conditions: Enroll and dose first patient in Phase 2 study. Q3 2023: Advanced Recurrent Ovarian Cancer: Announce Formal interim results. Q4 2023: Metastatic Pancreatic Cancer: Begin clinical trial: Post-COVID Conditions: Complete patient enrollment in Phase 2 study. In addition to executing on our clinical development, we have a number of corporate initiatives we are committed to in 2023, which include building diversity among our Board of Directors. We are actively working to identify individuals with key leadership and expertise and look forward to providing updates as those plans come to fruition. Another priority for us is to maintain active communication with the investment community. With this in mind, we plan to commence quarterly conference calls in the first quarter of 2023."

08:48 EST Snail announces new updates of ARK: Survival Evolved, ARK: TSOTF - Snail announced new updates to the popular ARK franchise, including the regional launch of ARK: Ultimate Survivor Edition on Nintendo Switch and the console launch of ARK: The Survival of the Fittest. In partnership with Grove Street Games, ARK: The Ultimate Survivor Edition and the first DLC, Scorched Earth, are now officially available in Japan, Hong Kong, Taiwan, and South Korea for Nintendo Switch players. The ARK: Ultimate Survivor Edition includes ARK: Survival Evolved, along with a series of DLCs: Scorched Earth, Aberration, Extinction, and Genesis Parts 1 & 2. Players can experience everything that the ARK franchise has to offer in this definitive collection, adding up to thousands of hours of gameplay. The other DLCs are scheduled to launch over time.

08:48 EST Exela Technologies announces updates to 2023 operational performance objectives - Exela Technologies announced updates to its 2023 operational performance improvement objectives. During the fourth quarter, the Company announced operational performance improvement targets by focusing on automation led efficiencies. The company has identified additional savings to help restore historically higher margins relative to recent financial reporting periods and plans to right-size the organization in the face of continuing tight job markets and higher employee costs. "Automation initiatives are leading to process improvements across operating functions which are beginning to provide cost savings. Additionally, we have continued to execute cost management measures throughout the organization and the team continues to expect revenue to stabilize. As we bring all these initiatives to fruition, we expect to improve operational efficiencies over time," said Shrikant Sortur, CFO of Exela Technologies. Exela expects savings in the range of $65M-$75M for 2023, including the initiatives announced in Q4 2022. The Company's actions include headcount optimization, real estate reduction and increased cloud usage. The Company's global workforce is expected to shrink; however, the Company will continue to maintain substantial flex capacity through its cloud-based WFA platforms to quickly ramp growth as needed.

08:45 EST Ciena on track to achieve three year revenue CAGR outlook of 10%-12%, says CEO

08:43 EST 3D Systems introduces VSP Connect portal - 3D Systems announced VSP Connect, a centralized, cloud-based surgical planning portal that integrates automated workflows and artificial intelligence. As the latest addition to the company's VSP surgical planning solutions, VSP Connect empowers device manufacturers and surgeons with real-time patient case visualization and improved collaboration capabilities. VSP Connect is powered by Enhatch, with whom the company entered a partnership in 2022 to scale personalized medical device delivery. The solution incorporates Enhatch's AI and automation technologies with 3D Systems' FDA-cleared workflows for patient-specific solutions, including advanced software, expert planning services, personalized implant and instrument design, and industry-leading 3D printers and manufacturing processes. This combination improves visibility for healthcare systems and medical device manufacturers and streamlines the preoperative planning process - helping make personalized procedures more efficient while delivering improved outcomes.

08:42 EST Apollo Commercial closes two financing facilities - Apollo Commercial Real Estate Finance announced the Company closed two financing facilities, including one asset backed facility and one revolving credit facility. The first facility is a master repurchase agreement with Banco Santander, S.A. New York Branch. The facility provides a maximum advance of $300.0 million for the financing of qualifying commercial mortgage loans and has an initial term of two years, with a one-year extension option. The second facility is a revolving credit facility administered by Bank of America, N.A. The facility provides up to $170.0 million of financing secured by qualifying commercial mortgage loans and real property owned assets and has a term of three years.

08:41 EST Blue Star Foods reports second half of 2022 performance at RAS Salmon division - Blue Star Foods announces that its wholly-owned RAS subsidiary, Taste of BC Aquafarms, has successfully reported key operating performance metrics for the second half of 2022. Average Fish Harvest Weight: Over the last 6 months, ending December 31, 2022, the average fish harvest weight has been 1898g. The company targets a minimum of weight of 2000g for its Steelhead Salmon product. Average Harvest Downgrade Percentage: Over the last 6 months, ending December 31, 2022, the total harvest downgrade percentage was 5.04%. This metric measures the number of fish at harvest that we did not bring to market at full price in the last stage of the lifecycle. Average Feed Conversion Ratio: Over the last 6 months, ending December 31, 2022, we have achieved a feed conversion ratio of 1.19KG Feed/Kg, versus the industry standard for open net FCR of 1.20 KG feed/kg. Ben Atkinson, the President of Taste of BC added, "Over the second half of 2022 we were able to increase biomass within our pilot facility an additional 10MT to 50MT. Unprecedented high temperatures stressed the capabilities of the chilling system within our pilot facility which led to poorer growth performance and elevated mortality during the summer months. As a result, total harvest volume was below target for the remainder of the year with the expectation that volumes will increase substantially in the first quarter 2023. A higher downgrade percentage is the result of our decision to prioritize culture space for our best performing cohorts by harvesting some slower growing fish. Overall, our fish are growing to expectations and continue to validate the model used to design our upcoming expansion facility."

08:39 EST Dentsply Sirona announces $150M accelerated share repurchase program - DENTSPLY SIRONA announced that it has entered into an accelerated share repurchase agreement with Goldman Sachs & Co. LLC to repurchase $150M of its common stock. The ASR agreement will be completed under Dentsply Sirona's current share repurchase authorization. Under the terms of the ASR, Dentsply Sirona will initially receive delivery of approximately 3.1 million shares. The final number of shares will be based on the average of the daily volume-weighted average stock prices of Dentsply Sirona common stock during the valuation period of the ASR, less a discount and subject to adjustments. The resulting adjustments may affect the total amount expended or the aggregate number of shares repurchased. Final settlement of the ASR is expected to be completed before the end of the second quarter of 2023.

08:36 EST Surgalign on track to achieve target cash savings of $30M-$35M in 2023 - Surgalign Holdings provided updates on its previously announced restructuring plan. On November 8, 2022, Surgalign's Board of Directors approved a restructuring plan intended to help the Company drive growth in the most valuable and profitable parts of its business. The approved plan included product portfolio rationalization in the domestic markets, and a scale down of its international business which will continue throughout 2023. Additionally, as part of the restructuring plan, the Company reduced its workforce in December of 2022, cut non-essential spending, and realigned resources to support growth of its Digital Health and core hardware assets. The primary focus of the planned restructuring has centered on product line rationalization. Surgalign targeted products with declining revenue and more limited growth prospects based on investments, as well as low and negative ROI profiles. The Company estimates that approximately 70% of total 2022 revenue was generated from roughly 30% of its product brands and believes that operating costs to support its other approximately 70% of its brands was too costly. Therefore, in January 2023, the Company began the process of removing those products from its portfolio. In anticipation of its product rationalization and the resulting downsizing of its offering, Surgalign announced in November 2022, plans to reduce its workforce. Notifications were provided and the Company executed on its plan, resulting in a reduction in force of approximately 20%. The combination of these efforts should enable the Company to significantly reduce its cash burn on a go-forward basis. Additionally, as part of its rationalization initiatives, the Company expects to incur an inventory write-down of approximately $12.5 - $15.5 million in the fourth quarter of 2022. By simplifying its offering, the Company anticipates it will be in a stronger position to service its customers, invest in its offering and execute its Digital Health strategy in the coming year. Furthermore, in an effort to extend its cash runway, Surgalign previously announced that it would explore all strategic avenues, including the potential divestiture of its assets, should opportunities arise. As announced on March 1, 2023, the Company closed on the sale of its Coflex and CoFix brands to Xtant Medical Holdings, Inc. for a total purchase price of $17.0 million. There has and continues to be interest in many of its other brands and the Company intends to continue to explore all strategic paths to unlock and enhance shareholder value.

08:33 EST Bannix clarifies position on excise tax, rational for extension periods - Bannix Acquisition announced that it is further clarifying its and Instant Fame's intent with respect to the excise tax liabilities associated with any redemptions. To clarify the language in the prior press release dated March 1, 2023, to mitigate the current uncertainty surrounding the implementation of the Inflation Reduction Act of 2022, in the event that the extension of the time period the Company has to complete an initial business combination is implemented, as described in the Company's definitive proxy statement, the Sponsor or a designee will indemnify the Company against any excise tax liabilities with respect to any redemption opportunities. As such, the Company will not, under any circumstances, withdraw any amounts from the Trust Account, including interest earned on the Trust Account, to pay for the Excise Tax. As previously stated, if the Extension is implemented, the Company plans to maintain the remaining amount in its trust account in an interest-bearing demand deposit account at a bank. The Company's Board of Directors, which, except for one director, have only served as directors since late October 2022, is undertaking to submit a proposed Business Combination to its shareholder for approval within the next nine months. The potential extension to the Extended Date, as defined in the Proxy Statement is needed for the time required to have each of the applicable regulators review the disclosure related to the Business Combination and ultimately have such Business Combination approved by the shareholders of the Company. The Board will use its reasonable best efforts to take the initial steps in presenting a potential Business Combination within the next three months.

08:28 EST Siyata Mobile deploys MCPTT solution for 2023 Special Olympics - Siyata Mobile announced the successful deployment of its mission critical push-to-talk solution for security and other communications at the 2023 Special Olympics New York Winter Games.

08:26 EST Ra Medical's Catheter Precision announces procedures using LockeT device - Ra Medical Systems announced that its wholly owned subsidiary, Catheter Precision, Inc., has announced the first series of procedures using the new LockeT device. Catheter Precision announced that shipping would begin on the week of February 13th and the first procedures would begin shortly thereafter. Within the first week, about thirty of the LockeT devices were used in electrophysiology procedures. .

08:24 EST Latin Metals provides update on AngloGold Ashanti exploration - Latin Metals provides an update regarding exploration activities on various properties included in an existing option agreement with AngloGold Argentina Exploraciones, under the terms of which AngloGold has an option to earn up to an 80% interest in the Company's Organullo, Ana Maria, and Trigal Gold projects. "AngloGold initiated exploration at Organullo only two weeks after signing the definitive option with Latin Metals in mid-2022, and it has advanced the project quickly to the point where it has drill-ready targets. The main advantage of working with major mining companies is the technical excellence and experience that they bring to a project," stated Keith Henderson, President & CEO of Latin Metals. "AngloGold has assembled an experienced technical team, and its exploration approach has resulted in the definition of new targets for drill testing at Organullo." AngloGold has received permits to complete a helicopter-borne magnetic and radiometric survey ahead of planned drilling. A drill permit has been submitted for up to 11,900m on the Breccia Hill, Axel, and Nemo targets. Identification of three advanced argillic alteration centres over a 6km strike length is a significant step forward for the project. AngloGold's current plans include 7,000m of Phase 1 drilling in 2023, which will be completed with two drill rigs subject to receipt of drill permits.

08:23 EST LendingTree repurchases $190M of Convertible Senior Notes due 2025 - LendingTree announced it has repurchased approximately $190M in aggregate principal amount of its outstanding 0.50% Convertible Senior Notes due 2025. In total, the company paid approximately $156.4M in cash through separate and individually negotiated transactions with certain holders to retire the notes.

08:22 EST Olink implementation of technology at NUS Medicine - Olink Holding announced that the Yong Loo Lin School of Medicine, National University of Singapore, NUS Medicine, has launched the NUS Medicine Protein Biomarker Discovery Core Facility, which will provide the Olink Explore 3072, Olink Explore 1536, Olink Target 96 and Target 48, and the recently launched Olink Flex platforms. These solutions for advanced protein biomarker research range from high-plex, high throughput discovery to more targeted biomarker studies. The launch of this core facility at NUS Medicine strengthens Olink's presence in the South Asia Pacific region, offering its highly innovative proteomics technologies to a wider audience. "With the NUS Medicine Protein Biomarker Discovery Core Facility we can support the local and regional research communities and empower researchers to seek a more comprehensive understanding of the biology and the pathophysiology of a disease. We welcome Olink as our primary proteomics partner in Singapore - their cutting-edge technology will provide detailed and comprehensive proteomics data covering all major biological pathways and processes," said Prof Chong Yap Seng, Lien Ying Chow Professor in Medicine, Dean, NUS Medicine.

08:20 EST Oatly Group announces results of 2023 Extraordinary General Meeting - Oatly Group announced the results of its Extraordinary General Meeting of shareholders held on 6 March, 2023. The EGM adopted, inter alia, the following resolutions: Resolution regarding amendments to the articles of association: The general meeting resolved, in accordance with the board of directors' proposal, that the number of shares in the Company shall be no less than 500,000,000 and no more than 2,000,000,000. The general meeting also resolved, in accordance with the board of directors' proposal, that the share capital of the company shall be no less than SEK 850,000 and no more than SEK 3,400,000. Authorization for the board of directors to resolve on new issue of shares and/or warrants and/or convertible bonds The general meeting resolved, in accordance with the board of directors' proposal, to revoke the previously given authorization and to authorize the board of directors, on one or more occasions during the period until the next annual general meeting, to resolve on new issue of shares and/or warrants and/or convertible bonds, corresponding to, in total, an amount of maximum USD 300,000,000 at the time of the issuances. The new issue of shares and/or warrants and/or convertible bonds may be performed with or without deviation from the shareholders' preferential rights. The board of directors' resolution may provide for payment in kind, payment against set-off and/or other terms.

08:18 EST Constellium discusses decarbonization initiatives at White House Roundtable - Jean-Marc Germain, CEO of Constellium, attended the Roundtable on Industrial Innovation and Decarbonization at the White House on March 3, 2023, together with senior-level officials of the Biden-Harris Administration, other major industrial companies and labor leaders, to share Constellium's efforts to reduce its greenhouse gas emissions and discuss how the Administration and the private sector can collaborate to address climate change issues. During this roundtable, Mr. Germain stated his support for public investments such as the ones made through the Inflation Reduction Act and the Bipartisan Infrastructure Law, which are essential to accelerate the transition to low-carbon. The Administration should ensure that the industry continues to operate in a fair environment during this transition, to protect jobs and competitiveness. Lastly, Mr. Germain highlighted the key role of recycling in a low-carbon economy, and advocated for deposit return programs to increase the recycling rate in the U.S. Constellium has disclosed its commitment to reduce its greenhouse gas emissions intensity by 30% in 2030 vs. 2021, and to increase its recycled input to at least 50% by 2030.

08:17 EST Guardion Health Sciences retains Atlantra to explore strategic alternatives - Guardion Health Sciences has retained Alantra as its financial advisor to assist with the strategic review and transaction process. Robert Weingarten, the Chairman of the Board of Directors of Guardion, stated, "We do not believe that the current market valuation of the Company accurately reflects the potential value of the Company and our clinical nutrition platform and brand. As fiduciaries on behalf our stockholders, the Guardion Board of Directors has been aggressively exploring a diverse range of strategic options over the past several months to enhance stockholder value. Our near-term objective is to identify and analyze strategic transactional opportunities, including a sale of the Company and/or its Viactiv brand, that would be expected to deliver enhanced value to stockholders. In this regard, we have engaged with Alantra, which has demonstrated a substantial record of experience and success in achieving significant results for clients in the Company's industry, and we are looking forward to working with the Alantra team to achieve our objectives". The Board of Directors has not set a timetable for the strategic review process, nor has it made any decisions related to any further actions or potential strategic alternatives at this time. There can be no assurances that this process will result in a transaction, or that if a transaction is completed, that it will ultimately enhance stockholder value. The Company does not intend to provide periodic updates until the Board of Directors determines that disclosure is appropriate and/or necessary under the circumstances.

08:16 EST DZS announces Optico Fiber leveraging DZS Access Edge, Subscriber EDGE - DZS announced that Optico Fiber is leveraging DZS Access EDGE and Subscriber EDGE solutions to launch what is expected to be the first 10 gigabit per second capable network on the island, bringing world-class, symmetrical multi-gigabit broadband services to the residents and businesses of Puerto Rico. A longtime DZS customer, Optico Fiber is expanding its existing DZS Velocity systems with system-on-a-card technology capable of supporting Gigabit PON, 10 Gigabit Symmetrical-PON, and 10Gbps point-to-point technologies out of any port, as well as the latest DZS Helix gateways to deliver whole home and business reach with WiFi technology. "DZS is proud and honored that our longtime partner Optico Fiber has leveraged our next- generation technologies to bring groundbreaking broadband services to Puerto Rico," said Charlie Vogt, President & CEO, DZS. "As more and more residential and business customers demand ultra-high-speed XGS-PON service levels to support use cases like working from home, latency-free gaming and connectivity for more mobile and IoT devices, forward-thinking "experience providers" like Optico Fiber will be ready with a robust network infrastructure upgradable to multi-gig services and the option of leveraging DZS Cloud EDGE software for ongoing experience and services enhancements if and when desired."

08:15 EST Retail Opportunity amends, extends unsecured credit facility - Retail Opportunity Investments amended and extended its $600 million unsecured credit facility, extending the maturity date by three years. Additionally, the interest rate will now be based on the Secured Overnight Financing Rate with an adjusted pricing grid, and a Sustainability Metric feature, and related pricing grid, were also added. Existing provisions to extend the maturity date for two consecutive six-month periods and an accordion feature, which allows the Company to increase the facility amount by an additional $600 million, were maintained. Additionally, ROIC amended its $300 million unsecured term loan, which will also now be based on SOFR. The accordion feature provision, which allows the Company to increase the facility amount by an additional $200 million, was maintained.

08:13 EST Enphase Energy expands IQ8 microinverter deployments in Illinois - Enphase Energy announced that installers of Enphase products in Illinois have seen growing deployments of Enphase Energy Systems powered by IQ8 Microinverters. "Our amazing network of installers is offering Illinois residents high-quality, reliable clean energy choices to power their lives at home," said Dave Ranhoff, chief commercial officer at Enphase Energy. "The Enphase Energy Systems powered by IQ8 Microinverters offers maximum control and a great customer experience, end to end."

08:13 EST AST SpaceMobile enters teaming agreement with Fairwinds Technologies - AST SpaceMobile announced a teaming agreement with Fairwinds Technologies to explore potential opportunities to jointly market AST SpaceMobile's planned services and innovative satellite technologies to the military market. Fairwinds develops innovative end-to-end communications solutions for the defense community and public sector agencies. Military forces have an operational need for high bandwidth, low latency and secure communications but often operate in areas without existing, trusted cellular coverage. Fairwinds is a U.S. Government prime contractor with experience designing solutions for defense and civilian agencies worldwide and an approved vendor for various government contract vehicles.

08:11 EST Silvergate falls after discontinuing Silvergate Exchange Network - Silvergate Capital announced on its website late Friday: "Effective immediately Silvergate Bank has made a risk-based decision to discontinue the Silvergate Exchange Network. All other deposit-related services remain operational." Both Compass Point and Wedbush downgraded the shares to sell-equivalent ratings following the news. Silvergate in premarket trading is down 7% to $5.37.

08:11 EST Lonza enters partnership agreement with Simris Alg AB - Simris Alg AB announced a framework collaboration agreement with Lonza Ltd, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, to commercialize Simris' ADC payload platform. Under the terms of the agreement, Lonza will integrate Simris' ADC payload technology into the Lonza Bioconjugation Toolbox and will gain the exclusive right to offer the technology to new and existing customers seeking novel payloads to develop into ADC medicines. The Lonza Bioconjugation Toolbox comprises a range of tailored solutions for the technology selection, development, and manufacturing of bioconjugates to advance the development of novel bioconjugate-based therapies. In return, Simris will promote Lonza to customers as its exclusive contract drug and manufacturing organization partner for services using its ADC technology.

08:08 EST Windtree announces results of marketing study related to istaroxime - Windtree Therapeutics is targeting cardiogenic shock as a potential indication for its drug candidate, istaroxime and today announces results of a recently completed market study. Innovative therapeutic interventions have the potential to decrease the long length of hospital stay associated with cardiogenic shock and its resulting high cost to the health care system. US hospital claims data obtained by Windtree show that in 2020 the US average cardiogenic shock patient length of stay in the hospital was 19.6 days and the median was 10 days. The US average length of stay for any hospitalization was 5.5 days. Additionally, the resources required to take care of these patients are substantial, frequently requiring ICU or CCU care where costs are high. These patients are at risk to experience clinical worsening that can lead to greater morbidity and mortality. "It is not common to see such a high unmet medical need, desirable market value and no competitive drug development," said Craig Fraser, CEO and President of Windtree Therapeutics. "Additionally, we are encouraged by the positive results of istaroxime's Phase 2 study in early cardiogenic shock that built upon previous positive results in acute heart failure and demonstrated a unique and attractive therapeutic profile. We believe that istaroxime has the therapeutic effect needed to navigate late-stage development and hopefully address the significant and critical needs of patients in cardiogenic shock. Given the relatively attractive cost and timing of development and, if approved, commercialization by a relatively small team, the program fits well with Windtree's strategy. We look forward to keeping investors updated on our clinical development progress." The Company conducted further research to determine the cardiogenic shock worldwide total market value and estimates it to be $1.25 billion, calculated by using cardiogenic shock patient US hospital claims and worldwide prevalence data multiplied by assumed various regional prices of drug treatment. To the Company's knowledge, there are no other drug candidates in clinical development for cardiogenic shock at this time.

08:07 EST Vistra to continue to repurchase $1B of stock in 2025, 2026 - As of Feb. 23, Vistra had ~$800M remaining under its $3.25B share repurchase authorization. On March 5, Vistra's board authorized an additional $1B of share repurchases, effective immediately. Vistra expects to complete the upsized ~$1.8B authorization by year-end 2024. In addition, Vistra continues to expect to repurchase $1B of stock each year 2025-2026, as well as pay $300M in aggregate dividends in each year 2023-2026, in line with its original capital allocation plan announced in November 2021.

08:07 EST Bragg Gaming launches new content in New Jersey - Bragg Gaming announced that it launched its new content and Remote Game Server with Resorts Digital Gaming, or RDG, in New Jersey. Proprietary content such as Fairy Dust and Dreamy Genie from Bragg's Atomic Slot Lab studio, as well as new exclusive premium content from the company's partner studios is now available to RDG's New Jersey customers.

08:05 EST Vistra raises aggregate share repurchase authorization by $1B - Remaining ~$1.8B authorization expected to be completed by year-end 2024.

08:05 EST AIRO enters plan of merger with Kernel Group to list on Nasdaq - Kernel Group Holdings announced that it has entered into a definitive business combination agreement with AIRO Group Holdings, a multi-faceted air mobility, autonomy & aerospace platform with differentiated technologies and capabilities that dynamically address high growth market trends across the entire aviation & aerospace ecosystem. The Merger Agreement provides AIRO with a path to becoming a publicly listed company through a new Delaware holding company, AIRO Group, Inc. that will acquire both Kernel and AIRO. Upon closing of the merger transaction, AIRO and Kernel will be wholly-owned subsidiaries of PubCo. PubCo common stock and warrants are expected to be listed on Nasdaq, under the symbols "AIRO" and "AIROW," respectively. Following the closing of the proposed transaction, Dr. Chirinjeev Kathuria will serve as the Chairman of the Board of Directors. The Board will consist of nine members including Joe Burns, John Uczekaj, Suren Ajjarapu, and Michael Peterson.The proposed Transaction was unanimously approved by the boards of directors of all parties, at an expected combined pro forma enterprise value of approximately $847 million, assuming no redemptions of current Kernel public stockholders. Prior to entering into the Merger Agreement, Kernel signed an agreement for an up to 7.7 million share backstop with Meteora. At the closing of the transaction, Kernel security holders will receive equivalent securities in PubCo in exchange for their Kernel securities, and both Kernel and AIRO will become wholly-owned subsidiaries of PubCo. Additionally, the proposed Transaction includes a contingent earnout payable to the AIRO stockholders and the sponsor. The proposed Transaction is expected to be completed in Q3 2023, subject to, among other things, the approval by Kernel stockholders, governmental, regulatory and third party approvals, satisfaction of minimum closing net tangible asset and cash requirements and the satisfaction or waiver of other customary closing conditions.

08:04 EST Landsea Homes moves corporate headquarters to Texas - Landsea Homes announced that the company is moving its corporate headquarters to Dallas, Texas from the current location in Newport Beach, California. The new headquarters office will be located at 1717 E. McKinney Street in Dallas and totals 7,716 square feet. Landsea Homes will occupy Suite 1000 on the 10th floor of the building.

08:02 EST Vistra to acquire Energy Harbor for $3B in cash - Vistra (VST) announced that it has executed a definitive agreement with Energy Harbor (ENGH), pursuant to which Energy Harbor will merge with and into a newly-formed subsidiary of Vistra. The transaction will combine Energy Harbor's nuclear and retail businesses with Vistra's nuclear and retail businesses and Vistra Zero renewables and storage projects under a newly-formed subsidiary holding company, referred to generally as "Vistra Vision." This combination creates a leading integrated retail electricity and zero-carbon generation company with the second-largest competitive nuclear fleet in the country, along with a growing renewables and energy storage portfolio. The agreement has been approved by both companies' boards of directors. Sufficient stockholder approval for the transaction has been committed through support agreements signed by a majority of the Energy Harbor stockholders. Total compensation will consist of $3 billion cash and a 15% equity interest in Vistra Vision. Most Energy Harbor shareholders will receive cash at closing, and the two largest shareholders, Avenue Capital Group and Nuveen, will receive a combination of cash and the 15% ownership interest. In addition, Vistra Vision will assume ~$430 million of net debt from Energy Harbor in the transaction. Vistra will continue to own 85% of Vistra Vision, as well as 100% of Vistra Tradition, Vistra's highly efficient gas and coal generation fleet. Vistra intends to finance the majority of the $3 billion of cash consideration through debt financing at Vistra Operations, with all or a portion of the debt expected to be invested in Vistra Vision via an inter-company loan. At closing, it is expected that the net debt of Vistra Vision will be ~$3.430 billion. Vistra has committed financing sufficient to fund the cash consideration and plans to execute long-term financings prior to the closing of the transaction. Vistra will not acquire Energy Harbor's legacy conventional generation fleet. Energy Harbor has previously signed definitive agreements to sell these assets to third parties.

07:42 EST Rallybio: Clinical proof-of-concept achieved in study for RLYB212 to stop FNAIT - Rallybio announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia, FNAIT. Results show that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects. Additional findings from the study show: The reduction in mean platelet elimination half-life was greater than 90% in both RLYB212 dose groups compared to placebo and was dose related. The broad range of pharmacokinetic and pharmacodynamic data allows substantive modeling to inform dose selection for a future registrational study. RLYB212 was observed to be well-tolerated with no serious adverse events reported. The Company expects to report data from the Phase 1b clinical study of RLYB212 at a scientific conference in 2023. "Our FNAIT development program has consistently demonstrated the effectiveness of anti-HPA-1a antibodies to rapidly eliminate HPA-1a positive platelets from the circulation of HPA-1a negative subjects," commented Roisin Armstrong, Ph.D., Rallybio's RLYB212 Program Lead. "We've also established in published nonclinical studies the association between rapid platelet elimination and prevention of HPA-1a alloimmunization, which can lead to negative and potentially life-threatening outcomes in FNAIT. Collectively, these data reinforce our belief on the potential for an anti-HPA-1a antibody to be a viable approach for preventing FNAIT and we look forward to continued advancement of the RLYB212 development program." Rallybio also announced that testing in the multi-dose cohort of its single-center Phase 1 trial in Europe began in the first quarter of 2023. This portion of the Phase 1 study will evaluate safety and pharmacokinetics of RLYB212 based on repeat dosing over 12 weeks in healthy male and female participants. The Company expects results from this cohort of subjects in the fourth quarter of 2023. Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, stated, "We are very pleased with the progress of our RLYB212 program. Throughout the program, we have carefully laid the groundwork to advance a product candidate that we believe can have a significant impact on the lives of expectant mothers and neonates. RLYB212 exemplifies Rallybio's enduring commitment to transforming the treatment of rare diseases with little to no therapeutic options." Given the favorable development profile of RLYB212 to date, the data generated to date for RLYB212, and the expected manufacturing and supply efficiencies for RLYB212, the Company also announced today that RLYB211, a plasma-derived polyclonal anti-HPA-1a antibody, will not be advanced further in clinical development.

07:40 EST Orezone Gold announces result from Phase III drill program at Bombore Gold Mine - Orezone Gold Corporation provides further results from its Phase III resource definition drill program from the P8P9 and Maga zones at its Bombore Gold Mine in Burkina Faso. Patrick Downey, President and CEO stated, "Our 2022 resource definition and expansion drill program has exceeded expectations, with several new high-grade zones now well-defined, all of which remain open to further expansion. The most recent results from P8P9 have delineated a new thick, well mineralized zone, with several high-grade intercepts over downhole widths ranging from 20m to 50m. This zone remains open in several directions including towards surface. All sulphide drill results have now been received and the resource update, which will incorporate over 100,000m of new drilling, is now well-advanced. The sulphide expansion study will provide the platform to significantly increase annual throughput and production at the Bombore operation and is expected to be released in Q3-2023."

07:40 EST Oscar Health announces renewed agreement with CVS Caremark - Oscar Health (OSCR) announced that it has renewed its Pharmacy Benefit Manager agreement with CVS Caremark (CVS) to provide Oscar members with continued access to CVS Caremark's pharmacy network. The agreement between the two organizations is expected to substantially lower costs for Oscar over the course of the contract period, beginning in 2023. As a part of the renegotiation, Oscar will continue to drive formulary design, with CVS Caremark providing pharmacy and health engagement services to complement Oscar's innovative member-focused approach to healthcare. "CVS Caremark provided an attractive offer that not only supports our strategic business imperatives but also provides continuity for our members," said Scott Blackley, Chief Transformation Officer of Oscar Health. "Ultimately, CVS Caremark proved to be best situated to support our increased scale and tech-enabled business and provide superior service, lower cost, and higher value." Oscar first engaged CVS Caremark to administer and manage its pharmacy benefits in 2012. The new agreement extends the relationship through 2026. Through their agreement, Oscar members will retain access to CVS Caremark's extensive network of pharmacies across the country.

07:39 EST Lordstown Motors expects to end Q1 with $150M-$170M in cash - The company said, "We expect to end the first quarter of 2023 with $150 to $170 million in cash and short-term investments, excluding any additional Foxconn funding, other equity sales or contingent liabilities. Relative to the fourth quarter of 2022, in the aggregate, we anticipate first quarter of 2023 SG&A and R&D to decline slightly, without the accelerated stock compensation, litigation accruals and asset write-downs, as R&D modestly increases with development activity, offsetting the larger decrease in SG&A."

07:37 EST Rallybio: Clinical proof-of-concept in study for RLYB212 to stop FNAIT - Rallybio announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia, FNAIT. Results show that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects. Additional findings from the study show: The reduction in mean platelet elimination half-life was greater than 90% in both RLYB212 dose groups compared to placebo and was dose related. The broad range of pharmacokinetic and pharmacodynamic data allows substantive modeling to inform dose selection for a future registrational study. RLYB212 was observed to be well-tolerated with no serious adverse events reported. The Company expects to report data from the Phase 1b clinical study of RLYB212 at a scientific conference in 2023. "Our FNAIT development program has consistently demonstrated the effectiveness of anti-HPA-1a antibodies to rapidly eliminate HPA-1a positive platelets from the circulation of HPA-1a negative subjects," commented Roisin Armstrong, Ph.D., Rallybio's RLYB212 Program Lead. "We've also established in published nonclinical studies the association between rapid platelet elimination and prevention of HPA-1a alloimmunization, which can lead to negative and potentially life-threatening outcomes in FNAIT. Collectively, these data reinforce our belief on the potential for an anti-HPA-1a antibody to be a viable approach for preventing FNAIT and we look forward to continued advancement of the RLYB212 development program." Rallybio also announced that testing in the multi-dose cohort of its single-center Phase 1 trial in Europe began in the first quarter of 2023. This portion of the Phase 1 study will evaluate safety and pharmacokinetics of RLYB212 based on repeat dosing over 12 weeks in healthy male and female participants. The Company expects results from this cohort of subjects in the fourth quarter of 2023. Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, stated, "We are very pleased with the progress of our RLYB212 program. Throughout the program, we have carefully laid the groundwork to advance a product candidate that we believe can have a significant impact on the lives of expectant mothers and neonates. RLYB212 exemplifies Rallybio's enduring commitment to transforming the treatment of rare diseases with little to no therapeutic options." Given the favorable development profile of RLYB212 to date, the data generated to date for RLYB212, and the expected manufacturing and supply efficiencies for RLYB212, the Company also announced today that RLYB211, a plasma-derived polyclonal anti-HPA-1a antibody, will not be advanced further in clinical development.

07:35 EST Global System Dynamics sponsor requests extension to complete combination - Global System Dynamics announced that its sponsor, DarkPulse, has requested a one-month extension to complete its initial business combination. Per the terms of the agreement, the sponsor will deposit an aggregate of $83,947.13 into the company's trust account for the benefit of its valued public stockholders. This additional contribution enables the company to extend the date by which the company has to complete its initial business combination for an additional one-month extension from March 9 to April 9. Such contribution effectively increases the pro rata portion of the funds available in the company's trust account in the event of the consummation of an initial business combination, liquidation, or other redemption event, by $0.0625 per share. The request has been approved by the company's board of directors, subject to the sponsor depositing the funds into the company's trust account by no later than March 9. The sponsor's contribution will be funded as a non-interest bearing loan that will either be paid upon earlier of consummation of an initial business combination or the company's liquidation.

07:32 EST Horace Mann increases quarterly dividend 3.1% to 33c per share - Horace Mann announced that its board of directors approved a 3.1% increase in the quarterly cash dividend to 33c per share. This represents an indicated annual dividend of $1.32 per share. The quarterly dividend is payable on March 31 to shareholders of record as of March 16.

07:26 EST A2Z Smart Technologies announces voting results of shareholders meeting - A2Z Smart Technologies Corp. announced that at the Company's Annual and Special General Meeting, held on February 28, 2023 in Toronto, all resolutions were duly passed by shareholders, including a rolling 10% stock option plan and the approval of the restricted share unit plan and increase the number of restricted share units under the RSU Plan by an additional 2,690,485 to 3,094,532.

07:24 EST Mydecine announces debt settlements - Mydecine Innovations Group announced share for debt settlements or debt owed to certain arms-length creditors, service providers and debtors of the Company. Pursuant to the debt settlement agreements entered into between the Company and each of the Creditors, the Debt will be converted into common shares in the capital of the Company. The Debt Settlements were undertaken by the Company to eliminate approximately $752,160 of liabilities. An aggregate of 1,299,998 Settlement Shares have been issued in satisfaction of the Debt. The Settlement Shares will be issued in reliance upon certain prospectus exemptions available under Canadian securities legislation. No new insiders or control persons were created as a result of the Debt Settlement.

07:21 EST Ocugen appoints Quan Vu to CFO, CBO - Ocugen announced the appointment of Quan Vu to Chief Financial Officer, CFO, & Chief Business Officer, CBO. Vu joined Ocugen on February 1, 2023, and has been working closely across multiple, key corporate functions-understanding short- and long-term business and financial needs of the Company along with the potential of its differentiated scientific platforms. With his additional appointment as Chief Financial Officer, and aside from his management and oversight of the finance and accounting functions, Vu will partner closely with Dr. Musunuri to enhance the Company's forward-looking, value-additive financial initiatives by leveraging the Company's anticipated clinical milestone achievements to bolster fundamental shareholder composition, expand interactions with the investor community, and ensure reputable capital markets and equity research support.

07:20 EST G. Willi-Food to construct new logistics center with $24.6M investment - G. Willi-Food International announces the receipt of a building permit for a new logistics center. The permit was received after a year and a half of planning and obtaining approvals from various authorities. The new logistics center will be built on property owned by the company in Yavne, adjacent to the old logistics center currently in operation and will allow the company to significantly expand its storage, collection and distribution space in order support the company's continued growth and increased activity in the Israeli food market, including expansion into new categories and increasing market share.The company currently expects to invest approximately $24.6M to be financed from the company's own resources.

07:19 EST Krystal Biotech appoints Catherine Mazzaco to boad of directors - Krystal Biotech announced the appointment of Catherine Mazzacco to its Board of Directors. Mazzacco was CEO and President of LEO Pharma, a privately owned global pharmaceutical company

07:17 EST Aclaris Therapeutics announces preliminary data from Phase 2 study of ATI-450 - Aclaris Therapeutics announced preliminary topline results from a 12-week, Phase 2a, multicenter, randomized, placebo-controlled clinical study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of zunsemetinib, an investigational oral MK2 inhibitor, in patients with moderate to severe hidradenitis suppurativa. The study did not meet its primary endpoint of change from baseline in inflammatory nodule/abscess count of zunsemetinib 50mg BID versus placebo at week 12. The study also did not meet the secondary efficacy endpoints assessed in the topline data, including percentage of patients achieving HiSCR-50. The placebo effect observed across all efficacy endpoints was higher than what has been observed in other published HS studies reported to date. Zunsemetinib was generally well tolerated. Safety findings were generally consistent with observations from prior clinical studies of zunsemetinib. The most common treatment-emergent adverse events in patients treated with zunsemetinib were dizziness, diarrhea, headache, creatine phosphokinase elevation and acne, with a majority deemed mild to moderate in severity. No serious adverse events and no serious and/or opportunistic infections were observed with patients treated with zunsemetinib. Pharmacokinetics/Pharmacodynamics: PK and PD were generally consistent with observations from prior clinical studies of zunsemetinib. A preliminary analysis of endogenous plasma cytokines and chemokines in patients with a confirmed dose of study treatment on the day of blood draw, demonstrated zunsemetinib dependent inhibition relative to placebo.

07:16 EST Tango Therapeutics announces inducement grants under Nasdaq listing rule - Tango Therapeutics announced that, effective March 1, 2023, the Compensation Committee of Tango Therapeutics' Board of Directors granted non-qualified stock options to purchase an aggregate of 637,000 shares of its common stock and an aggregate of 106,250 restricted stock units to two new employees under Tango Therapeutics' 2023 Inducement Plan; including 487,500 stock options and 81,250 RSUs to Adam Crystal, M.D., Ph.D. in connection with his acceptance of employment as Tango Therapeutics' President of Research and Development. The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The options have an exercise price of $5.20 per share, which is equal to the closing price of Tango Therapeutics' common stock on March 1, 2023. Each option will vest as to 25% of the shares underlying such option on February 27, 2024 and as to an additional 1/36th of the remaining shares underlying the option monthly thereafter, in each case, subject to each such employee's continued employment on each vesting date. Each RSU will vest as to one-third of the shares on February 5, 2024, (ii) one-third of the shares on February 3, 2025 and (iii) the final one-third of the shares on February 2, 2026, subject to each such employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan, which was approved in February 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.

07:15 EST Atai Life Sciences announces corporate updates, reduced workforce by 30% - Corporate Updates: As part of a strategic review of its pipeline and to enhance operational efficiency and focus, the Company has reduced its workforce by approximately 30%. The majority of the cost savings will result from a workforce reduction in general and administration and non-clinical development. The Company has extended its cash runway, which is now expected into 1H 2026.

07:14 EST Atai Life Sciences announces key pipeline, corporate updates - atai Life Sciences provided key clinical pipeline and corporate updates. Pipeline Updates:RL-007: The first patient was recently dosed in the phase 2b study of RL-007 in patients with CIAS. Initial results from this study are expected in the 2nd half of 2024. GRX-917: The clinical development plan has been updated to now proceed with a phase 2 study in patients. The updated plan is anticipated to generate the robust clinical data needed to best support potential registration. More details on the clinical development plan will be provided upon initiation of the study. The updated plan follows the positive results from the phase 1 single and multiple ascending dose study of GRX-917. In this trial, GRX-917 was well-tolerated. Additionally, GRX-917 had an improved pharmacokinetic profile relative to etifoxine and provided pharmacodynamic evidence of GABA receptor target engagement through qEEG. PCN-101: In January 2023, in conjunction with the phase 2a study results of PCN-101, atai announced it would further evaluate the data and work with its subsidiary Perception Neuroscience to determine next steps for the program. atai will continue to support Perception's development of PCN-101 through the IV-to-subcutaneous bridging study, which is currently on-track to be completed in the middle of 2023. In parallel, atai continues to work with Perception Neuroscience to explore strategic partnership options. COMP360: On February 28th, COMPASS Pathways announced an acceleration of the Pivotal Trial 1 part of the phase 3 program in treatment-resistant depression, with top line data now expected in the summer 2024.

07:13 EST BioCardia present data from Phase III CardiAMP Cell Therapy Heart Failure trial - BioCardia announces that detailed echocardiography data from the roll-in cohort of the Phase III CardiAMP Cell Therapy Heart Failure Trial is being presented at the American College of Cardiology annual meeting by Peter Johnston, M.D., Assistant Professor of Medicine and Site Principal Investigator at Johns Hopkins University. Results from the 10-patient roll-in cohort of the clinical trial showed that myocardial wall motion in the 16 regions of the heart was more often characterized as normal after the study treatment at one year follow-up, and at two-year follow-up, as measured by the blinded echocardiography core lab at Yale University: In this series, only 13 percent of heart segments in these patients were contracting normally before treatment; at one year, 25 percent were contracting normally and at two years, 29 percent were contracting normally- indicating a more than doubling of the number of heart segments characterized as having normal function post-procedure. In completely non-functioning heart segments, 17 of 56, or 30 percent, of those heart segments resumed wall motion by two years. The overall wall motion score index for all 16 segments in the heart was improved, decreasing from 2.4 at baseline to 2.0 at one year to 1.9 at two years. As a result of the restoration of myocardial wall motion, patients experienced an improvement in median left ventricular ejection fraction, which increased from 27 percent at baseline to 34 percent at one year, to 37 percent at two years.

07:11 EST BioLineRx announces collaboration with Washington University School of Medicine - BioLineRx announced a collaboration with Washington University School of Medicine in St. Louis to advance a Phase 1 clinical trial that will evaluate the safety and feasibility of the company's lead clinical candidate motixafortide to mobilize CD34+ hematopoietic stem cells for gene therapies in sickle cell disease, one of the most common genetic diseases globally. Currently available mobilization regimens can carry serious risks and side effects for patients with SCD or may not reliably yield optimal numbers of HSCs for gene therapy. The clinical trial is part of the company's long-term growth strategy for motixafortide across multiple therapeutic areas, including a potential future indication as a stem cell mobilization agent to support gene therapy development.

07:11 EST AxoGen appoints Began as EVP, General Counsel - Axogen announced the appointment of Marc Began as Executive Vice President, EVP. Additionally, effective March 20, 2023, Began will be Axogen's General Counsel, replacing Brad Ottinger, General Counsel and Chief Compliance Officer. As a member of the executive leadership team, Began will report directly to Karen Zaderej, Chairman, CEO and President, and will be responsible for all legal, business development, and compliance activities for Axogen. Began was most recently Executive Vice President, General Counsel, and Secretary of Abiomed.

07:10 EST Genius Group appoints Mark Basile as special counsel - Genius Group has retained attorney Mark Basile and his toxic debt litigation firm, The Basile Law Firm P.C., to act as Special Counsel to its legal team in the Company's complaint filed in the United States District Court Southern District of New York, Case Number 1:23-cv-01639 against Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, Ayrton Capital, LLC and Waqas Khatri/ This lawsuit was filed by Warshaw Burstein LLP of New York and Christian Levine Law Group LLC of Texas, two firms that possess extensive experience and achieved considerable success in litigating stock manipulation cases.

07:09 EST Bowman Consulting names Ryan Belyea Chief Digital Officer - Bowman Consulting Group announced that Ryan Belyea has been named to the newly created position of Chief Digital Officer, CDO . Belyea brings more than 25 years of industry experience, most recently as Vice President and Director for Digital at AECOM in the US and Latin America, where he established digital strategies and best practices for consulting engagements and project delivery. He has led the delivery of revenue generating technology solutions across all disciplines in the infrastructure sector, including digital transformation strategies, solutions integration, geographic information systems , building information modeling , reality capture, data mining and application, and asset management.

07:09 EST American Lithium to fast-track completion of PFS for Falchani - American Lithium has appointed DRA Global as lead engineer to coordinate completion of a Pre-Feasibility Study on the Company's Falchani Lithium Project in Southern Peru. As part of this process, Stantec Consulting will also prepare an updated mineral resource estimate on Falchani which will involve the reclassification of existing resource categories, as well as including new drill data from the recent hydrology drilling which commenced in August 2022. The Company also announces that it has restarted additional hydrology drilling at Falchani, with full support from the local communities. This drilling is part of the Environmental Impact Assessment that was commenced in August 2022. The first step towards completing a PFS will involve updating the Company's existing Preliminary Economic Assessment for Falchani, which is expected to expedite the PFS process. The work required to update the PEA started in the second half of 2022 with a focus on incorporating Sulphate of Potash and Cesium by-products, which are expected to provide a valuable contribution to the project economics. It will also incorporate the updated mineral resource data being prepared by Stantec. As announced in June 2022, work by the Australian Nuclear Science and Technology Organisation validated Sulphate of Potash as a viable and important by-product at Falchani. ANSTO is now focused on adding Sulphate of Potash and Cesium circuits to the overall flow sheet, while maintaining / increasing the impressive lithium extraction rates and battery grade purity. It is anticipated that this work will be finalized in the near term. Finally, the PEA will also be updated to reflect the material increase in lithium carbonate pricing since the original report published in early 2020, which used a $12,000 per tonne LCE price. Recent studies on other lithium projects globally have used up to US$24,000 per tonne LCE reflecting material price rises in the commodity over the last 2 years and anticipated long-term pricing. Higher pricing is even more applicable to Falchani given the potential to precipitate battery grade lithium carbonate through its flow sheet.

07:07 EST Grifols enters R&D agreement with Selagine - Selagine announced that it has entered into a research, development and sublicense agreement with Grifols for the development and commercialization of immunoglobulin eye drops for dry eye disease. Under the agreement, Selagine will receive an upfront payment and annual collaboration fee. In addition, Grifols has committed to fund the development of immunoglobulin eye drops through FDA approval, which will be managed collaboratively by Grifols and Selagine, including the clinical, manufacturing and regulatory activities required for FDA approval for dry eye disease indication. Upon commercialization, Selagine will receive tiered royalties on net sales and milestone payments upon achievement of certain annual sales thresholds. Selagine will share a part of the royalties with UIC.

07:06 EST Mindset Pharma, PharmAla complete first sale of pharmaceutical grade psilocybin - Mindset Pharma and PharmAla Biotech Holdings announced that PharmAla has completed the first sale of a quantity of Mindset's cGMP psilocybin under their exclusive sales agreement. The psilocybin is being purchased by Reset Mind Sciences Limited, a Western Australian based company focused on psychedelic medicines, and a subsidiary of ASX listed Little Green Pharma. Reset recently received human research ethics committee approval for a clinical trial investigating psilocybin assisted psychotherapy protocols for patients with treatment resistant major depressive disorder.

07:05 EST Wolters Kluwer appoints divisional CEOs, creates fifth division - Wolters Kluwer announced three divisional CEO appointments that will set the stage for accelerated growth at the company. Karen Abramson, formerly CEO of Tax & Accounting, is now the CEO of the new Corporate Performance & ESG division. Jason Marx, formerly leading North America Tax & Accounting, is the new CEO of Wolters Kluwer Tax & Accounting. Steve Meirink, formerly leading Compliance Solutions, is the new CEO of Wolters Kluwer Financial & Corporate Compliance. The appointments follow Wolters Kluwer's strategic decision announced in February of this year to create a 5th division, Corporate Performance & ESG. CP & ESG has been established to meet the growing demand from corporations and banks for integrated financial, operational, and ESG performance management and reporting solutions. CP & ESG brings together Wolters Kluwer's global software businesses that focus on corporate performance management, environmental health and safety, and risk. By leveraging the natural synergy that exists across these businesses, the company will be able to better serve its customers and drive accelerated growth by extending and integrating its current product portfolio.

07:03 EST Entrada Therapeutics expects cash to fund requirements into 2H25 - Cash, cash equivalents and marketable securities were $188.7 million as of December 31, 2022, compared to $215.6 million as of September 30, 2022 and $291.1 million as of December 31, 2021. The Company anticipates that its existing cash, cash equivalents and marketable securities, together with the proceeds received under the Vertex Agreement, ongoing research support and the anticipated achievement of certain near-term milestones under the Vertex Agreement will be sufficient to extend our cash runway into the second half of 2025, supporting the Company's expansion and continued development of EEV-therapeutic candidates targeting Duchenne as well as other indications beyond neuromuscular diseases.

06:50 EST AstraZeneca says Enhertu met prespecified criteria for ORR in DESTINY-PanTumor02 - Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo's Enhertu met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pretreated patients, AstraZeneca announced. Enhertu is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. The DESTINY-PanTumor02 Phase II trial is evaluating the efficacy and safety of Enhertu in patients with locally advanced, unresectable, or metastatic previously treated, HER2-expressing solid tumours not eligible for curative therapy, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare cancers. The primary endpoint of the trial is investigator-assessed confirmed ORR and investigator-assessed duration of response, or DoR, is a key secondary endpoint. The data will be presented at an upcoming medical meeting and shared with global regulatory authorities. Reference Link

06:43 EST Construction Partners announces Greg Hoffman to succeed Alan Palmer as CFO - Construction Partners announced, in accordance with the company's management succession plan, that Greg Hoffman will succeed Alan Palmer as CFO, effective following the close of business on March 31. Palmer will continue with the company in an advisory and mentoring role. As CFO, Hoffman will assume full leadership of the financial team, expanding his oversight of the accounting and financial operations. Hoffman has served as the company's senior VP, finance since April 2021.

06:34 EST NGL Energy Partners to sell marine assets for $111.65M in cash - NGL Energy Partners announced the signing of two definitive agreements to sell all of its marine assets for $111.65M in cash in the aggregate. NGL provided waterborne transportation of refined products and crude oil for a diversified group of customers which include major oil refineries on the Gulf Coast with these assets. NGL's marine fleet consists of 13 towboats and 25 tank barges. The transaction is expected to close at the end of this month, subject to customary closing conditions.

06:22 EST Armata Pharmaceuticals announces topline results for SWARM-P.a. trial - Armata Pharmaceuticals announced topline results from the completed Phase 1b/2a SWARM-P.a. trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients. The SWARM-P.a. trial was a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study that evaluated the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD, of AP-PA02. Data indicate that AP-PA02 was well-tolerated with a treatment emergent adverse event profile similar to placebo. Only mild, self-limited adverse events possibly related to study drug were reported in a few subjects. PK findings confirm that AP-PA02 can be effectively delivered to the lungs through nebulization with minimal systemic exposure. Single ascending doses, or SAD, and multiple ascending doses, or MAD, resulted in a proportional increase in exposure as measured in induced sputum. Additionally, achieved exposures were relatively consistent from subject to subject. Bacterial levels of P. aeruginosa in the sputum were measured at several timepoints and compared to baseline levels prior to study drug administration. Trends suggest improvement in bacterial load reduction for subjects treated with AP-PA02 at end of treatment as compared to placebo after ten days of dosing. Importantly, for subjects with the highest average exposure of susceptible phage, there was durability of approximately two-log reduction from end of treatment to end of study. PK/PD analysis indicates significant microbiological impacts in the subjects with highest exposures. Armata also announced that it has dosed the first subject in its Tailwind study of nebulized AP-PA02 in patients with non-cystic fibrosis bronchiectasis, or NCFB. The Tailwind study is a double blind, randomized, placebo-controlled trial that will evaluate the safety, tolerability, and efficacy of inhaled AP-PA02 as monotherapy, as well as in combination with inhaled antibiotics. Pharmacokinetic data from SWARM-P.a. were used to design an optimized AP-PA02 dosing regimen for the Tailwind study. Insights from Tailwind will be important for the concurrent design of the Phase 2b cystic fibrosis study, which will be powered to evaluate the efficacy and durability of phage response over time.

06:14 EST Salem Media acquires George Gilder's line of investment products - Salem Media Group announced that it has acquired George Gilder's investment newsletters Gilder's Technology Report, Gilder's Technology Report PRO, Gilder's Moonshots, Gilder's Private Reserve and Gilder's Guideposts. It also launched a new website for George Gilder, www.GilderReport.com.

06:10 EST Orchard Therapeutics expects cash to fund operations into 2025 - Moving forward, the company expects its cash burn rate in 2023 to continue declining as compared to 2022 due to an anticipated increase in revenue from Libmeldy product sales and ongoing management of operating expenses. The company expects R&D expenses to decrease in 2023 as compared to 2022 following the completion of pre-BLA regulatory activities for OTL-200. In addition, the company expects SG&A expenses to decrease slightly in 2023 as compared to 2022 with incremental investments in the commercialization of Libmeldy to be offset by further reductions in G&A expenses. With the $34M of up-front proceeds from financing, the company expects that its existing cash, cash equivalents and investments will fund its anticipated operating, debt service and capital expenditure requirements into 2025, with the potential for additional runway extension upon subsequent closings from financing.

06:01 EST Adaptimmune, TCR2 Therapeutics to combine in all-stock transaction

05:10 EST UMC reports February revenue NT$16.93M, down 18.64%

05:05 EST CME Group to launch offshore Renminbi options - CME Group announced that it will launch options on its existing U.S. Dollar / Offshore Chinese Renminbi futures on April 3, pending regulatory review.